NCT04323566View on ClinicalTrials.gov

Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

April 1, 2028

Study Completion Date

December 1, 2028

Conditions
Obsessive-Compulsive DisorderObsessive-Compulsive BehaviorSchizophreniaDelusional DisorderBrief Psychotic DisorderSchizo Affective DisorderOther PsychosesUnspecified Psychosis
Interventions
DRUG

Rituximab

"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"

Trial Locations (1)

75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Uppsala University Hospital

OTHER